Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran 1199663911, Iran.
Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran 1199663911, Iran; Department of Dermatology, School of Medicine Razi Hospital, Tehran University of Medical Sciences, Tehran 1199663911, Iran.
Int Immunopharmacol. 2021 Dec;101(Pt B):108186. doi: 10.1016/j.intimp.2021.108186. Epub 2021 Oct 25.
Alopecia areata (AA) is a chronic disorder and the best treatment regimen for it is unknown. Currently, one of the best documented treatment modalities for AA is topical immunotherapy.
To evaluate the safety and efficacy of a novel method (multi-concentration patch test) versus standard protocol for topical immunotherapy.
A prospective randomized clinical trial was conducted on 30 patients with Alopecia areata, half of them received DPCP with a novel method using multi-concentration patch test to determine the optimal initiating concentration of DPCP (case group) and the other half experienced immunotherapy according to the standard protocol (control group). Percentage of hair regrowth after 6 months of treatment and the incidence of drug-related adverse effects were evaluated and compared between the two groups. (IRCT registration code: IRCT20141209020250N5).
Absolute and relative hair regrowth percentages were reported 25% and 41.49% in case group and 8.2% and 14.21% in control group respectively. Considerable response (more than 75% hair regrowth) was observed in 4 (26.6%) patients in case and 1 (6.6%) patient in control group. The clinical response was initiated about 7 weeks sooner in case compared to the control group (14 versus 7.38 weeks, P: 0.001). Overall, clinical response was higher in patients received new protocol, compared to control group. Moreover, patients who experienced new protocol had a higher level of treatment satisfaction in comparison with patients having standard protocol (P: 0.012).
This study revealed the effectiveness and safety of the novel multi-concentration patch test DPCP therapy for AA and its priority to conventional method, at least in terms of shortened duration of DPCP immunotherapy.
斑秃（AA）是一种慢性疾病，目前尚不清楚其最佳治疗方案。目前，斑秃的最佳治疗方法之一是局部免疫疗法。
评估一种新方法（多浓度斑贴试验）与局部免疫疗法标准方案相比的安全性和有效性。
对 30 例斑秃患者进行前瞻性随机临床试验，其中一半患者接受 DPCP 治疗，采用多浓度斑贴试验确定 DPCP 的最佳起始浓度（病例组），另一半患者根据标准方案进行免疫治疗（对照组）。评估并比较两组患者治疗 6 个月后的毛发再生百分比和药物相关不良反应发生率。（IRCT 注册号：IRCT20141209020250N5）。
病例组绝对和相对毛发再生百分比分别为 25%和 41.49%，对照组分别为 8.2%和 14.21%。病例组有 4 例（26.6%）患者出现明显反应（毛发再生超过 75%），对照组有 1 例（6.6%）患者出现明显反应。病例组的临床反应开始时间比对照组早约 7 周（14 周对 7.38 周，P：0.001）。总的来说，与对照组相比，接受新方案的患者临床反应更高。此外，与接受标准方案的患者相比，接受新方案的患者治疗满意度更高（P：0.012）。
本研究表明，多浓度斑贴试验 DPCP 治疗斑秃安全有效，且与传统方法相比，至少在缩短 DPCP 免疫治疗持续时间方面具有优势。
